These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7656786)

  • 21. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
    Kehoe SM; Williams NL; Yakubu R; Levine DA; Chi DS; Sabbatini PJ; Aghajanian CA; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2009 May; 113(2):228-32. PubMed ID: 19254808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of large bowel obstruction in advanced ovarian cancer with intraluminal stents.
    Carter J; Valmadre S; Dalrymple C; Atkinson K; Young C
    Gynecol Oncol; 2002 Jan; 84(1):176-9. PubMed ID: 11748998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.
    Black D; Iasonos A; Ahmed H; Chi DS; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2007 Oct; 107(1):66-70. PubMed ID: 17614125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eight years experience of high-powered endoscopic diode laser therapy for palliation of colorectal carcinoma.
    Courtney ED; Raja A; Leicester RJ
    Dis Colon Rectum; 2005 Apr; 48(4):845-50. PubMed ID: 15747077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
    Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-expandable metallic stent placement as palliative treatment of obstructed colorectal carcinoma.
    Maetani I; Tada T; Ukita T; Inoue H; Yoshida M; Saida Y; Sakai Y
    J Gastroenterol; 2004; 39(4):334-8. PubMed ID: 15168244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bowel resections in cancers of the ovary ].
    Kauffmann P; Le Bouëdec G; Dauplat J
    J Gynecol Obstet Biol Reprod (Paris); 1993; 22(5):501-8. PubMed ID: 7693794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small bowel obstruction: conservative vs. surgical management.
    Williams SB; Greenspon J; Young HA; Orkin BA
    Dis Colon Rectum; 2005 Jun; 48(6):1140-6. PubMed ID: 15906139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of adverse surgical outcome in the management of malignant bowel obstruction.
    Medina-Franco H; García-Alvarez MN; Ortiz-López LJ; Cuairán JZ
    Rev Invest Clin; 2008; 60(3):212-6. PubMed ID: 18807733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intestinal obstruction in cancer patients. An assessment of risk factors and outcome.
    Gallick HL; Weaver DW; Sachs RJ; Bouwman DL
    Am Surg; 1986 Aug; 52(8):434-7. PubMed ID: 3729182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management and prognosis of advanced ovarian cancer associated with bowel metastasis and obstruction].
    Wu M; Lang J; Huang R
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):617-20. PubMed ID: 9275459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of intestinal obstruction in ovarian cancer.
    Krebs HB; Helmkamp BF
    Oncology (Williston Park); 1989 May; 3(5):25-31; discussion 31-2, 35-6. PubMed ID: 2491443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer.
    Chi DS; Phaëton R; Miner TJ; Kardos SV; Diaz JP; Leitao MM; Gardner G; Huh J; Tew WP; Konner JA; Sonoda Y; Abu-Rustum NR; Barakat RR; Jaques DP
    Oncologist; 2009 Aug; 14(8):835-9. PubMed ID: 19684071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does the index operation influence the course and outcome of adhesive intestinal obstruction?
    Matter I; Khalemsky L; Abrahamson J; Nash E; Sabo E; Eldar S
    Eur J Surg; 1997 Oct; 163(10):767-72. PubMed ID: 9373228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
    Cook S; Penson R; Duska L; Nikrui N; Goodman A; Fuller A; Seiden M
    Gynecol Oncol; 2000 Apr; 77(1):48-54. PubMed ID: 10739690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series.
    Caceres A; Zhou Q; Iasonos A; Gerdes H; Chi DS; Barakat RR
    Gynecol Oncol; 2008 Mar; 108(3):482-5. PubMed ID: 18190953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.